Plasmid analysis detected two plasmids of Ͼ100 kb and ca. 75 kb in isolate YC. Using ampicillin (100 g/ml) and sodium azide (100 g/ml; Sigma-Aldrich, Saint-Quentin-Fallavier, France) as selective agents and sodium azide-resistant Escherichia coli J53 as the recipient strain, the ca.-75-kb plasmid was self-conjugative and conferred ␤-lactam resistance patterns for E. coli transconjugants similar with respect to the MICs obtained, except for those for cefoxitin, cefotaxime, ceftazidime, and aztreonam, which were lower than those for the parental strain (Table 1) . A ␤-lactamase extract from a transconjugant culture subjected to analytical isoelectric focusing (8) identified two ␤-lactamases with pI values of 5.4 and 6.8. Using primers for the detection of Ambler class A and class B ␤-lactamase genes (7, 8) , PCR experiments followed by sequencing identified a ␤-lactamase gene coding for the carbapenemase KPC-2 (pI 6.8) and the narrow-spectrum TEM-1 (pI 5.4), which were also identified from K. pneumoniae YC.
Then, by the use of a series of successive PCR primers, the 2.8-kb surrounding sequences of the bla KPC-2 gene were found to be identical to those surrounding the same bla KPC-2 gene from a Salmonella isolate from Maryland (6) .
This report identified a carbapenem-hydrolyzing ␤-lactamase KPC in France that likely resulted from an intercontinental transfer of the KPC producer from the United States. Up to the time of this discovery, plasmid-mediated KPC enzymes had been a unique feature of the United States, whereas most other broad-spectrum antibiotic resistance genes have been reported in the United States after their initial discoveries elsewhere. The identification of KPC enzymes is worrisome, since they hydrolyze expanded-spectrum cephalosporins and carbapenems and thus could jeopardize therapy for serious infections caused by major nosocomial pathogens. In addition, their detection, based on careful interpretation of reduced carbapenem susceptibility in Enterobacteriaceae, remains difficult. a CLA, clavulanic acid at a fixed concentration of 2 g/ml; TZB, tazobactam at a fixed concentration of 4 g/ml.
